Healthcare Industry News: bone graft
News Release - July 11, 2006
Smith & Nephew Endoscopy Acquires Privately-Held Osteobiologics, Inc.Provides the only off-the-shelf bioabsorbable implant for articular cartilage repair on the market in Europe
ANDOVER, Mass., July 11 (HSMN NewsFeed) -- Smith & Nephew's (NYSE: SNN ; LSE: SN ) Endoscopy division, the global leader in arthroscopic surgery, announced today its acquisition of privately-held, San Antonio-based OsteoBiologics, Inc. (OBI).
OBI markets innovative bioabsorbable bone graft substitutes (BGS) in Europe to repair cartilage defects in the knee, and offers the TruFit(TM) BGS Plugs in the U.S. as a bone void filler. OBI's products are an exciting addition to Smith & Nephew's existing comprehensive arthroscopy portfolio and will be sold through Smith & Nephew Endoscopy's global selling force.
"We're extremely pleased to welcome OBI and their employees to the Smith & Nephew family," commented Mike Frazzette, president, Smith & Nephew Endoscopy. "Their proprietary technology will allow us to provide even more choices to surgeons when it comes to treating injuries within the joint."
Smith & Nephew has agreed to pay a net consideration of $72.3m in cash for OBI, whose 2005 sales revenues were $3.3 million. The acquisition is expected to reduce earnings by $7m in the second half of 2006 and be broadly neutral in 2007.
OBI's primary product marketed in Europe, TruFit(TM) CB is a one-step arthroscopic procedure for repairing bone and articular cartilage defects. Cartilage is a protective covering of the articular surfaces of bones that reduces friction and provides flexibility within the joint. Cartilage defects are often a result of traumatic injury or degenerative conditions and are often found in conjunction with meniscal tears or ACL injuries. There is strong evidence that articular cartilage defects can lead to osteoarthritis.
Currently, less than 20 percent of cartilage defects in the knee are treated due to the lack of an efficacious and patient-friendly solution.
"Efficacious repair of articular cartilage defects represents a significant unmet need of sports medicine surgeons," said Joe Darling, VP, Marketing, Smith & Nephew Endoscopy. "The availability of OBI's simple-to-use TruFit(TM) CB will allow these defects to be treated before they lead to additional damage within the joint.
In addition, OBI is a powerful complement to our comprehensive knee repair product offering and further strengthens our industry-leading arthroscopy portfolio."
The TruFit implants are manufactured with poly (D,L-lactide-co-glycolide) polymer, formed into a bi-layered cylindrical scaffold that is absorbed by the body within six to nine months.
About Smith & Nephew:
Smith & Nephew (NYSE: SNN, LSE: SN) (http://www.smith-nephew.com) is a global medical technology business, specializing in Endoscopy, Orthopaedic Reconstruction, Orthopaedic Trauma and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeon and professional healthcare customers, with whom its name is synonymous with the highest standards of performance, innovation and trust. The company has more than 8,500 employees and operates in 33 countries around the world and generated sales of nearly $2.6 billion.
This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim," "plan," "intend," "anticipate," "well-placed," "believe," "estimate," "expect," "target," "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew meniscal knee repair technology delivers 0% re-operation rate and 100% meniscal healing at six months shows first ever study of horizontal cleavage tears
Smith & Nephew Launches the CONQUEST FN(TM) Femoral Neck Fracture System, a Fresh Approach to Hip Preservation Versus Current Treatment Options
Smith & Nephew launches new FLOW 90(TM) Wand at ISAKOS joining its innovative collection of COBLATION(TM) technology and shoulder repair portfolios